VERTEX PHARMACEUTICALS INC / MA

VRTX - CIK 0000875320

Market cap$110.46 B

Rank#136

SEC filings1,000

VERTEX PHARMACEUTICALS INC / MA trades as VRTX and has a market capitalization of $110.46 B, making it the #136 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $12.00B, up 8.9% from the prior year and net income of $3.95B. This page tracks VERTEX PHARMACEUTICALS INC / MA through 1,000 SEC filings, with financial statements and metrics updated as new reports are filed.

Key metrics

Revenue (latest FY)$12.00BFY 2025

Net income (latest FY)$3.95BFY 2025

Operating cash flow (latest FY)$3.63BFY 2025

Total assets (latest FY)$25.64BFY 2025

Net margin32.9%latest FY

Financial performance

Over the last 9 fiscal years VERTEX PHARMACEUTICALS INC / MA's revenue grew from $1.70B to $12.00B, a compound annual growth rate of 24.2%. Net profit margin expanded from -6.6% to 32.9% over the same period - every figure below comes from the company's audited annual filings.

VRTX annual revenueView details

Key statistics

Market cap: $110.46 B
Share price (derived)market cap / shares outstanding: $435.22
P/E ratio (trailing FY): 27.9
EPS (diluted)FY 2025: $15.32
Shares outstandingas of 2026-04-30: 0.25B
Total equityas of 2026-03-31: $19.36B
Return on equity: 20.4%
Cash & equivalentsas of 2026-03-31: $5.49B

Latest filings

Filing	Type	Filed
Insider trade	4	2026-05-19
Insider trade	4	2026-05-19
Insider sale notice	144	2026-05-15
Insider sale notice	144	2026-05-15
SCHEDULE 13G/A	-	2026-05-14
SCHEDULE 13G/A	-	2026-05-14
Insider trade	4	2026-05-14
S-8 POS	-	2026-05-13

Browse the full filing history (1,000 filings)

Recent press releases

Vertex Reports Second Quarter 2025 Financial Results
Total revenue increased 12% to $2.96 billion compared to the second quarter of 2024, primarily driven by the continued performance of cystic ...
Vertex Provides Pipeline and Business Updates in Advance of ...
Vertex realized its goal for greater than $100 million of CASGEVY revenue in 2025, reflecting more than 60 patients receiving infusions of CASGEVY. At the ...
Vertex Reports Fourth Quarter and Full Year 2025 Financial Results
Vertex Reports Fourth Quarter and Full Year 2025 Financial Results ; FY 2026 ; Total revenue. $12.95 to $13.1 billion ; Non-CF product revenue.
Vertex Reports First Quarter 2025 Financial Results
Total revenue of $2.77 billion , a 3% increase compared to Q1 2024; raised the low end of total revenue guidance by $100 million to a new ...
Vertex Reports Third Quarter 2025 Financial Results
Total revenue increased 11% to $3.08 billion compared to the third quarter of 2024, primarily driven by the continued performance of cystic ...

Similar companies

The largest companies sharing VERTEX PHARMACEUTICALS INC / MA's SEC industry classification (pharmaceutical preparations).

LLYEli Lilly and Company$1.072 T VRTX vs LLY

JNJJohnson & Johnson$573.98 B VRTX vs JNJ

ABBVAbbVie Inc.$399.47 B VRTX vs ABBV

MRKMerck & Co., Inc.$293.16 B VRTX vs MRK

AZNAstraZeneca PLC$286.27 B VRTX vs AZN

Frequently asked questions

What is VERTEX PHARMACEUTICALS INC / MA's market cap?

VERTEX PHARMACEUTICALS INC / MA (VRTX) has a market capitalization of $110.46 B as of 2026-06-10, ranking #136 among US-listed companies.

How much revenue does VERTEX PHARMACEUTICALS INC / MA make?

VERTEX PHARMACEUTICALS INC / MA reported revenue of $12.00B for fiscal year 2025, an increase of 8.9% year over year.

Is VERTEX PHARMACEUTICALS INC / MA profitable?

Yes. VERTEX PHARMACEUTICALS INC / MA reported net income of $3.95B in its latest fiscal year.

Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.